



上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

() P C

(Stock Code: 02196)

2014 FIRST QUARTERLY REPORT

1 .Q (2) 1 .10

201 “Company”, “Group”).

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
C

2 A, 201.

A M . C M . F ;
M . G G , M . G , M . P M . K L ;
M . H J , D . M . L M A D M .
C H .

* F

The shareholding status of the Top 10 unrestricted shareholders of tradable shares

Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
[Illegible]	20,111	[Illegible]
[Illegible]	5,250	[Illegible]
[Illegible]	2,172	[Illegible]
[Illegible]	1,217	[Illegible]
[Illegible]	1,000,000	[Illegible]
[Illegible]	1,222	[Illegible]
[Illegible]	1,020	[Illegible]
[Illegible]	12,111	[Illegible]
[Illegible]	11,177	[Illegible]
[Illegible]	10,120	[Illegible]
[Illegible]	[Illegible]	[Illegible]

N: [Illegible]

3 SIGNIFICANT EVENTS

1. The company has not reported any significant events during the period.

A, b A, b

2014.03.31

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
Assets	2,070,121.20	1,700,250	121.76%	Increase in assets due to the increase in equity and liabilities.
Liabilities	2,250,152	12,171,172	18.11%	Decrease in liabilities due to the decrease in equity and assets.
Income Statement				
Items	Current Amount	Amount of the last period	Ratio of change	Reasons
	(Jan - Mar 2014)	(Jan - Mar 2013)		
Revenue	14,550,000	1,125,000	1292.31%	Significant increase in revenue due to the expansion of business operations.
Operating Expenses	1,252,202	2,070,110.1	60.49%	Decrease in operating expenses due to cost-cutting measures.
Operating Income	13,297,798	2,250,152	590.78%	Significant increase in operating income due to the increase in revenue and decrease in expenses.
Other Income	10,100	2,200,010	0.46%	Decrease in other income due to the decrease in non-recurring items.
Income before taxes	13,307,898	1,050,142	1267.31%	Significant increase in income before taxes due to the increase in operating income.
Income tax expense	2,110,000	0,000	211.00%	Increase in income tax expense due to the increase in taxable income.
Net Income	11,197,898	1,050,142	1066.41%	Significant increase in net income due to the increase in income before taxes and decrease in tax expense.

() 2/ 7 ▲ bⁿ x 201, ... m' ... (/ x, x^d, x) ...
... m ... m ... * (上 ...) ... m ...

4 APPENDICES

Consolidated Balance Sheet

31 M 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Monetary assets	1,020,000,000	1,000,000,000
Accounts receivable	1,100,000,000	1,100,000,000
Prepaid expenses and other receivables	1,200,000,000	1,200,000,000
Inventory	200,000,000	200,000,000
Other current assets	1,000,000,000	1,000,000,000
Intangible assets	1,000,000,000	1,000,000,000
Investments	1,000,000,000	1,000,000,000
Other non-current assets	1,000,000,000	1,000,000,000
Non-current assets:		
Property, plant and equipment	1,000,000,000	1,000,000,000
Intangible assets	1,000,000,000	1,000,000,000
Investments	1,000,000,000	1,000,000,000
Other non-current assets	1,000,000,000	1,000,000,000

Income Statement of the Company

J... - M... 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
	2,107,152.00	207,200.02
	-1,207,207.11	7,207,207.11
	2,107,227.00	2,107,152.00
	2,072,277.00	2,107,227.00
	-1,027,207.00	2,107,152.00
	5,000.00	5,000.00
	2,000,000.00	5,111.20
	-1,207,207.00	2,107,152.00
	-1,207,207.00	2,107,152.00
(1) b	-0.00	0.12
(2) d	-0.00	0.12
		5,207.00
	-1,207,207.00	2,107,071.20

Consolidated Statements of Cash Flows

J - M 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
I. Cash flow generated from operating activities:		
Net income	1,022,227,100	212,370,222
Adjustments to reconcile net income to cash flow from operating activities:		
Depreciation and amortization	1,706,700	1,200,000
Provision for doubtful accounts	0	0
Change in accounts receivable	12,771	21,700
Change in accounts payable	1,117,100	1,000,200
Change in prepayments		
Change in other receivables		
Change in other payables		
Change in income taxes payable		
Change in deferred income taxes		
Change in other non-current assets		
Change in other non-current liabilities		
Change in cash and cash equivalents	2,858,678	2,423,122
II. Cash flow generated from investing activities:		
Capital expenditures	(1,000,000)	(1,000,000)
Acquisition of intangible assets	(2,000,000)	(2,222,222)
Disposal of fixed assets	1,000,000	1,000,000
Disposal of intangible assets	2,100,000	1,222,222
Disposal of other non-current assets	(2,000,000)	(2,000,000)
Change in cash and cash equivalents	(1,900,000)	(1,999,999)
Change in cash and cash equivalents	958,678	423,122

Consolidated Statements of Cash Flows (Continued)

J — M 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
Proceeds from the issuance of long-term debt	5,170,000	
Proceeds from the issuance of short-term debt	5,170,000	
Proceeds from the issuance of preferred stock	1,225,125	1,070,000
Proceeds from the issuance of common stock		
Proceeds from the sale of treasury stock	215,525	
Proceeds from the sale of property, plant and equipment	2,200,000	1,070,000
Proceeds from the sale of investments	125,225	1,070,000
Proceeds from the sale of other assets	20,225	1,225,000
Proceeds from the sale of cash equivalents	0,000,000	5,170,000
Proceeds from the sale of other cash equivalents	1,000,000	2,000,000
Proceeds from the sale of other cash equivalents	0,000,000	2,000,000
Proceeds from the sale of other cash equivalents	1,000,000	1,000,000
IV. Effects of exchange rate fluctuations on cash and cash equivalents	0,000,000	0,000,000
V. Net increase of cash and cash equivalents	10,000,000	10,000,000
Proceeds from the issuance of long-term debt	2,000,000	2,000,000
VI. Closing balance of cash and cash equivalents	2,000,000	2,000,000

Statements of Cash Flows of the Company (Continued)

J u n e - M a y 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
Proceeds from the issuance of shares:		
Initial public offering	5,000,000.00	
Private placement		
Exercise of warrants	1,275,700.00	5,500,000.00
Exercise of convertible preferred stock	2,275,700.00	5,500,000.00
Proceeds from the sale of treasury stock		
Proceeds from the sale of equity securities	10,122,222.22	10,500,000.00
Proceeds from the sale of debt securities	1,722,222.22	2,000,000.00
Proceeds from the sale of real estate	1,500,000.00	2,000,000.00
Proceeds from the sale of other assets	500,000.00	2,211,000.00
IV. Effects of exchange rate fluctuations on cash and cash equivalents	12,000.00	2,000.00
V. Net increase of cash and cash equivalents	11,522,222.22	2,111,000.00
VI. Closing balance of cash and cash equivalents	1,122,222.22	1,000,000.00

* F o r m o r e i n f o r m a t i o n , p l e a s e r e f e r t o t h e n o t e s t o t h e f i n a n c i a l s t a t e m e n t s .